CDX-1140 clinical trials
Also written CDX-1140.
How each study uses CDX-1140 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CDX-1140 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 10
Providence Health & Services (2) · National Cancer Institute (NCI) (2) · University of Southern California (1) · Craig L Slingluff, Jr (1) · Celldex Therapeutics (1) · Roswell Park Cancer Institute (1) · University of Texas Southwestern Medical Center (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test CDX-1140.
- Dec 2026Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Phase 1 · Providence Health & Services
- Jan 2027In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsPhase 1 · University of Southern California
- Mar 2027Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerPhase 2 · Roswell Park Cancer Institute
- Apr 2027Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Phase 1 · Providence Health & Services
- Nov 2027Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerPhase 2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses CDX-1140 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05849480Written as CDX-1140
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06980038Written as Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRecruitingPhase 2Roswell Park Cancer InstituteNCT05231122Written as Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerRecruitingPhase 1University of Texas Southwestern Medical CenterNCT05029999Written as CDX-1140
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingPhase 1University of Southern CaliforniaNCT04616248Written as Anti-CD40 Agonist Monoclonal Antibody CDX-1140
- Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingPhase 1Providence Health & ServicesNCT05349890Written as CDX-1140
- Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingPhase 1Providence Health & ServicesNCT04520711Written as CDX-1140
- Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer PatientsTerminatedPhase 2Washington University School of MedicineNCT04536077Written as CDX-1140
- Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)CompletedPhase 1/2Craig L Slingluff, JrNCT04364230Written as CDX-1140
- A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal AdenocarcinomaTerminatedPhase 1HiberCell, Inc.NCT05484011Written as CDX-1140
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedPhase 1Celldex TherapeuticsNCT03329950Written as CDX-1140
- FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic RadiotherapyTerminatedPhase 1/2Albert Einstein College of MedicineNCT04491084Written as anti-CD40 antibody (CDX-1140)
Codes
What other systems call CDX-1140 · ClinicalTrials.gg INT017506
- UNII (FDA) OWK8BG0FO6CDX-1140One source FDA
- NCI Thesaurus C150558Anti-CD40 Agonist Monoclonal Antibody CDX-1140One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OWK8BG0FO6 | CDX-1140 | One source FDA |
| NCI Thesaurus | C150558 | Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.